Article
Hematology
Tanya Siddiqi, Jacob D. Soumerai, Kathleen A. Dorritie, Deborah M. Stephens, Peter A. Riedell, Jon Arnason, Thomas J. Kipps, Heidi H. Gillenwater, Lucy Gong, Lin Yang, Ken Ogasawara, Jerill Thorpe, William G. Wierda
Summary: Lisocabtagene maraleucel, an autologous CD19-directed CAR T-cell therapy, shows promising safety and efficacy in patients with relapsed/refractory CLL/SLL, providing a potential new treatment option for these patients who develop resistance to current therapies.
Article
Oncology
Jennifer R. Brown
Summary: In relapsed chronic lymphocytic leukemia, treatment choices depend on various factors such as risk profile, prior therapy, and patient comorbidities. Different drug options are suitable for different situations of patients, and close monitoring is needed for treatment when the disease progresses.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2021)
Article
Hematology
John F. Seymour, Thomas J. Kipps, Barbara F. Eichhorst, James D'Rozario, Carolyn J. Owen, Sarit Assouline, Nicole Lamanna, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Clemens Mellink, Brenda Chyla, Anesh Panchal, Tong Lu, Jenny Q. Wu, Yanwen Jiang, Marcus Lefebure, Michelle Boyer, Arnon P. Kater
Summary: The MURANO trial demonstrated that Venetoclax plus Rituximab is superior to Bendamustine plus Rituximab in terms of progression-free survival and overall survival in relapsed/refractory chronic lymphocytic leukemia (CLL) patients. The study also found that undetectable minimal residual disease (uMRD) can be achieved more often with Venetoclax plus Rituximab, and the long-term implications of uMRD in this treatment regimen were explored.
Article
Oncology
Liana Nikolaenko, Tingting Liu, Alexey V. Danilov
Summary: The treatment landscape of chronic lymphocytic leukemia (CLL) has been significantly altered with the introduction of novel targeted therapies, including PI3K inhibitors like idelalisib and duvelisib approved for therapy of relapsed/refractory (R/R) CLL. Duvelisib, a selective dual PI3K delta/gamma inhibitor, has shown meaningful efficacy in high-risk R/R CLL patients and may be particularly suitable for those who are suboptimal candidates for BTK inhibitors. Monitoring and managing adverse events is crucial for the continued role of duvelisib in therapy of R/R CLL.
EXPERT REVIEW OF ANTICANCER THERAPY
(2021)
Article
Hematology
Ewa Paszkiewicz-Kozik, Wojciech Michalski, Michal Taszner, Monika Mordak-Domagala, Joanna Romejko-Jarosinska, Wanda Knopinska-Posluszny, Jacek Najda, Anna Borawska, Monika Chelstowska, Monika Swierkowska, Anna Dabrowska-Iwanicka, Agata Malenda, Agnieszka Druzd-Sitek, Robert Konecki, Beata Kumiega, Michal Osowiecki, Beata Ostrowska, Tomasz Szpila, Marcin Szymanski, Lukasz Targonski, Katarzyna Domanska-Czyz, Lidia Poplawska, Sebastian Giebel, Andrzej Lange, Andrzej Pluta, Jan Maciej Zaucha, Grzegorz Rymkiewicz, Jan Walewski
Summary: This study evaluated the efficacy and safety of ofatumumab in combination with iphosphamide, etoposide, and cytarabine (O-IVAC) in relapsed or progressing diffuse large B-cell lymphoma (DLBCL) patients. The overall response rate (ORR) for O-IVAC was 54.5%, with a median progression-free survival (PFS) and event-free survival (EFS) of 16.3 months each, and a median overall survival (OS) of 22.7 months. Age, ECOG performance status, and prior therapy lines were independent predictors of survival.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Review
Oncology
Oluwatobi Odetola, Shuo Ma
Summary: This review emphasizes that the purpose of treatment for relapsed/refractory CLL is disease control and delay of progression rather than cure. The article reviews the concept of relapsed CLL, factors predisposing to relapse, and available therapeutic options. Recent findings show that targeted therapies such as continuous BTK inhibitors or fixed duration venetoclax plus anti-CD20 monoclonal antibody therapy have established superiority over chemoimmunotherapy in relapsed CLL and are now the preferred standard of care treatment.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS
(2023)
Article
Hematology
Emily C. Liang, Aya Albittar, Jennifer J. Huang, Alexandre Hirayama, Erik L. Kimble, Andrew J. Portuguese, Aude Chapuis, Mazyar Shadman, Brian G. Till, Ryan D. Cassaday, Filippo Milano, Hans -Peter Kiem, Stanley R. Riddell, Cameron J. Turtle, David G. Maloney, Jordan Gauthier
Summary: High response rates have been reported in CD19-targeted CAR T-cell therapy for relapsed/refractory CLL. Factors associated with duration of response include maximum standardized uptake value and bulky disease. Complete response at day +28, negative measurable residual disease at day +28 by flow cytometry and next-generation sequencing, higher peak CD8(+) and CD4(+) CAR T-cell expansion, and longer CAR T-cell persistence are associated with longer progression-free survival.
Review
Oncology
Florian Simon, Jan-Paul Bohn
Summary: This research aims to provide an overview of evidence-based sequencing of therapies in relapsed/refractory CLL. Results suggest that patients with late relapse benefit from identical retreatment, while class switch is favorable for those with short-lived remissions or progressive disease. Treatment for patients previously exposed to both BTK and BCL2 inhibitors is still a medical need, with promising efficacy shown in early trials of noncovalent BTKI.
CURRENT ONCOLOGY REPORTS
(2023)
Review
Immunology
Zhongwang Wang, Hui Zhou, Jing Xu, Jinjin Wang, Ting Niu
Summary: This systematic review and meta-analysis evaluated the efficacy and safety of Duvelisib in different relapsed or refractory lymphoid neoplasms. The results showed that Duvelisib has favorable efficacy in treating relapsed or refractory CLL/SLL, iNHL, MCL, and AITL. Proper identification and management can mitigate the risk and severity of Duvelisib treatment.
FRONTIERS IN IMMUNOLOGY
(2023)
Letter
Oncology
Xin Jin, Meng Zhang, Rui Sun, Hairong Lyu, Xia Xiao, Xiaomei Zhang, Fan Li, Danni Xie, Xia Xiong, Jiaxi Wang, Wenyi Lu, Hongkai Zhang, Mingfeng Zhao
Summary: This study evaluates the efficacy and safety of CLL-1 CAR-T cell therapy in adults with R/R AML. All patients developed cytokine release syndrome (CRS), but none developed CAR-T cell-related encephalopathy syndrome (CRES). Despite severe pancytopenia in all patients, a 70% complete response (CR) or CR with incomplete hematologic recovery (CRi) rate was achieved.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Article
Oncology
Seval Akpinar, Mehmet Hilmi Dogu, Serhat Celik, Omer Ekinci, Ipek Yonal Hindilerden, Mehmet Sinan Dal, Eren Arslan Davulcu, Atakan Tekinalp, Fehmi Hindilerden, Busra Gokce Ozcan, Tuba Hacibekiroglu, Mehmet Ali Erkurt, Metin Bagci, Sinem Namdaroglu, Gulten Korkmaz, Oktay Bilgir, Gulsum Akgun Cagliyan, Hacer Berna Afacan Ozturk, Istemi Serin, Tarik Onur Tiryaki, Duzgun Ozatli, Serdal Korkmaz, Turgay Ulas, Bulent Eser, Burhan Turgut, Fevzi Altuntas
Summary: In this study, we evaluated the safety and efficacy of single-agent ibrutinib for relapsed/refractory CLL in real-world settings. The results demonstrated good safety and efficacy, with a median overall survival of 52 months.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2022)
Article
Hematology
Laurie H. Sehn, Mark Hertzberg, Stephen Opat, Alex F. Herrera, Sarit Assouline, Christopher R. Flowers, Tae Min Kim, Andrew McMillan, Muhit Ozcan, Violaine Safar, Gilles Salles, Grace Ku, Jamie Hirata, Yi Meng Chang, Lisa Musick, Matthew J. Matasar
Summary: Polatuzumab vedotin plus bendamustine and rituximab (pola + BR) has been approved for the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) based on the results of the GO29365 study. The study reported updated results from the randomized arms and the extension cohort, showing that pola + BR is an effective treatment option with a well-characterized safety profile.
Article
Hematology
Julia Driessen, Gerben J. C. Zwezerijnen, Heiko Schoeder, Marie Jose Kersten, Alison J. Moskowitz, Craig H. Moskowitz, Jakoba J. Eertink, Martijn W. Heymans, Ronald Boellaard, Josee M. Zijlstra
Summary: We developed a prognostic model for progression-free survival (PFS) in patients with relapsed or primary refractory classical Hodgkin lymphoma (R/R cHL) using baseline quantitative F-18-fluorodeoxyglucose positron emission tomography (PET) radiomics features and clinical characteristics. The model can help predict PFS outcomes and guide risk-stratified treatment strategies for R/R cHL patients.
Article
Oncology
Barbara Vannata, Anna Vanazzi, Mara Negri, Sarah Jayne Liptrott, Anna Amalia Bartosek, Monica Miani, Alessandro Di Sanzo, Franco Cavalli, Emanuele Zucca, Anastasios Stathis
Summary: The combination of bendamustine with ofatumumab showed activity with acceptable toxicity in relapsed/refractory MZL patients in this small phase II trial.
HEMATOLOGICAL ONCOLOGY
(2021)
Article
Oncology
Guoqiang Lin, Yanming Zhang, Lei Yu, Depei Wu
Summary: The study evaluated the effectiveness of CAR-T cells targeting CLL-1 combined with PD-1 silencing therapy for AML, suggesting it as a potential immunotherapy for relapsed or refractory AML.
MOLECULAR MEDICINE REPORTS
(2021)
Article
Oncology
Peter Hillmen, Barbara Eichhorst, Jennifer R. Brown, Nicole Lamanna, Susan M. O'Brien, Constantine S. Tam, Lugui Qiu, Maciej Kazmierczak, Keshu Zhou, Martin Simkovic, Jiri Mayer, Amanda Gillespie-Twardy, Mazyar Shadman, Alessandra Ferrajoli, Peter S. Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Osterborg, Habte A. Yimer, Tommi Salmi, Meng Ji, Jessica Yecies, Adam Idoine, Kenneth Wu, Jane Huang, Wojciech Jurczak
Summary: The study compared the efficacy and safety of zanubrutinib and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. The results showed that zanubrutinib had better outcomes in terms of efficacy, atrial fibrillation rate, and cardiac safety compared to ibrutinib.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Hematology
Juan A. Pineyroa, Joan Cid, Alexandru Vlagea, Gloria Carbasse, Paola Henao, Noemi Bailo, Valentin Ortiz-Maldonado, Nuria Martinez-Cibrian, Marta Espanol, Julio Delgado, Alvaro Urbano-Ispizua, Miquel Lozano
Summary: This study retrospectively evaluated the impact of donor- and procedure-related characteristics on the collection efficiency of lymphocytes during the collection of autologous T lymphocytes. The results showed that the Amicus device was associated with higher collection efficiency of lymphocytes (p = 0.01) and lower collection efficiency of platelets (p < 0.01) compared to the Optia device.
Letter
Biophysics
Fermin Sanchez-Guijo, Cristina Avendano-Sola, Lina Badimon, Juan A. Bueren, Josep M. Canals, Joaquim Delgadillo, Julio Delgado, Cristina Eguizabal, Maria-Eugenia Fernandez-Santos, Damian Garcia-Olmo, Gloria Gonzalez-Aseguinolaza, Manel Juan, Francisco Martin, Rosario Mata, Nuria Montserrat, Antonio Perez-Martinez, Jose A. Perez-Simon, Felipe Prosper, Alvaro Urbano-Ispizua, Agustin G. Zapata, Anna Sureda, Jose M. Moraleda
BONE MARROW TRANSPLANTATION
(2023)
Letter
Hematology
Ilaria Del Giudice, Luca Vincenzo Cappelli, Julio Delgado, Carsten Utoft Niemann, Michael Asger Andersen, Emelie Hamotal Curovic Rotbain, Kathrine Aarup, Renata Walewska, Andrea Visentin, Marina Deodato, Anna Maria Frustaci, Chiara Cavalloni, Massimo Gentile, Mohamed A. Yassin, Deepesh Lad, Lydia Scarfo, Max Flogegard, Mattias Mattsson, Sara Raponi, Caterina Ilari, Irene Della Starza, Ester M. Orlandi, Alessandra Tedeschi, Livio Trentin, Gianpietro Semenzato, Anna Guarini, Paolo Ghia, Emili Montserrat, Robin Foa
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
John N. Allan, Ian W. Flinn, Tanya Siddiqi, Paolo Ghia, Constantine S. Tam, Thomas J. Kipps, Paul M. Barr, Anna Elinder Camburn, Alessandra Tedeschi, Xavier C. Badoux, Ryan Jacobs, Bryone J. Kuss, Livio Trentin, Cathy Zhou, Anita Szoke, Christopher Abbazio, William G. Wierda
Summary: The CAPTIVATE study demonstrates that fixed-duration ibrutinib plus venetoclax is effective in controlling chronic lymphocytic leukemia, including patients with high-risk genomic features. This treatment provides durable progression-free survival and similar overall survival rates.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Jennifer A. Woyach, Paolo Ghia, John C. Byrd, Inhye E. Ahn, Carol Moreno, Susan M. O'Brien, Daniel Jones, Leo W. K. Cheung, Elizabeth Chong, Kevin Kwei, James P. Dean, Danelle F. James, Adrian Wiestner
Summary: Acquired mutations in BTK or PLCG2 genes are associated with clinical progressive disease in CLL patients. Mutations in these genes are rare in previously untreated patients but more common in relapsed/refractory CLL patients. Time to detection of BTK mutations is longer in relapsed/refractory CLL patients.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Pablo Mozas, Cristina Lopez, Marta Grau, Ferran Nadeu, Guillem Clot, Sara Valle, Marta Kulis, Alba Navarro, Joan Enric Ramis-Zaldivar, Blanca Gonzalez-Farre, Alfredo Rivas-Delgado, Andrea Rivero, Gerard Frigola, Olga Balague, Eva Gine, Julio Delgado, Neus Villamor, Estella Matutes, Laura Magnano, Ramon Garcia-Sanz, Sarah Huet, Robert B. Russell, Elias Campo, Armando Lopez-Guillermo, Silvia Bea
Summary: This study investigated the genetic alterations specific to follicular lymphoma (FL) patients with different clinical behaviors. Through analysis of diagnostic and relapse tissue samples, several driver losses and frequently altered genes/regions were identified. The study also established the functional consequences of mutations. These findings expand our knowledge on FL and have potential implications for risk stratification and targeted therapies.
HEMATOLOGICAL ONCOLOGY
(2023)
Article
Oncology
C. Mircea S. Tesileanu, Sotirios Michaleas, Rocio Gonzalo Ruiz, Segundo Mariz, Babs O. Fabriek, Paula B. van Hennik, Jutta Dedorath, Bruna Dekic, Christoph Unkrig, Andreas Brandt, Janet Koenig, Harald Enzmann, Julio Delgado, Francesco Pignatti
Summary: Asciminib is a high-affinity tyrosine kinase inhibitor that targets BCR-ABL1 protein kinase. It has been approved by the European Commission for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia patients who have previously received at least 2 TKIs. The clinical efficacy and safety of asciminib were evaluated in the phase III ASCEMBL study.
Article
Oncology
Ana Belen Moreno-Castano, Sara Fernandez, Helena Ventosa, Marta Palomo, Julia Martinez-Sanchez, Alex Ramos, Valentin Ortiz-Maldonado, Julio Delgado, Carlos Fernandez de Larrea, Alvaro Urbano-Ispizua, Olaf Penack, J. M. Nicolas, Adrian Tellez, Gines Escolar, Enric Carreras, Francesc Fernandez-Aviles, Pedro Castro, Maribel Diaz-Ricart
Summary: CAR-T cell-based immunotherapy for hematological malignancies may lead to cytokine release and immune effector cell-associated neurotoxicity syndromes. This study found that markers of endothelial dysfunction, innate immunity activation, and hemostatic imbalance could potentially be used as laboratory tools for predicting and differentiating toxicities, as well as determining their severity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Hematology
Andrea Visentin, Thomas Chatzikonstantinou, Lydia Scarfo, Anargyros Kapetanakis, Christos Demosthenous, Georgios Karakatsoulis
Summary: In this retrospective international multicenter study, the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders infected by SARS-CoV-2 were described. The study also investigated the development of post-COVID condition. The data showed that patients infected in the most recent phases of the pandemic had lower hospitalization rates, ICU admission rates, and mortality compared to those infected in the initial phases. Overall survival improved throughout the phases. Age, comorbidity, and CLL-directed treatment were identified as risk factors for mortality. A significant number of patients developed post-COVID condition, characterized by fatigue, dyspnea, lasting cough, and impaired concentration. The severity of infection was the only risk factor for developing post-COVID. Further investigations are warranted to understand the impact of COVID-19 on CLL patients.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Hematology
John F. Seymour, John C. Byrd, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard R. Furman, Susan O'Brien, Jennifer R. Brown, Talha Munir, Anthony Mato, Stephan Stilgenbauer, Naghmana Bajwa, Paulo Miranda, Kara Higgins, Ellie John, Marianne de Borja, Wojciech Jurczak, Jennifer A. Woyach
Summary: ELEVATE-RR trial showed that acalabrutinib has noninferior progression-free survival and lower incidence of key adverse events compared to ibrutinib in previously treated chronic lymphocytic leukemia patients. Post hoc analysis further characterized the adverse events of acalabrutinib and ibrutinib. It was found that acalabrutinib had higher incidence rates of headache and cough, while ibrutinib had higher rates of diarrhea, joint pain, urinary tract infection, back pain, muscle spasms, and dyspepsia. Ibrutinib also had higher rates of atrial fibrillation/flutter, hypertension, and bleeding. The discontinuation rate due to adverse events was lower with acalabrutinib. The overall event-based analyses and adverse event burden scores demonstrated that ibrutinib had a higher burden of adverse events compared to acalabrutinib, particularly in atrial fibrillation, hypertension, and bleeding.
Article
Oncology
Heribert Playa-Albinyana, Fabian Arenas, Romina Royo, Ariadna Giro, Irene Lopez-Oreja, Marta Aymerich, Monica Lopez-Guerra, Gerard Frigola, Silvia Bea, Julio Delgado, Pablo M. Garcia-Roves, Elias Campo, Ferran Nadeu, Dolors Colomer
Summary: This study established patient-derived xenograft models to investigate the molecular characteristics and evolution of chronic lymphocytic leukemia (CLL) and Richter transformation (RT). The models revealed the subclonal heterogeneity and clonal evolution of RT cells during PDX generation. Transcriptomic analysis showed high oxidative phosphorylation and low B-cell receptor signaling in RT, and an OXPHOS inhibitor circumvented drug resistance. The study provides valuable insights into the intrinsic features of RT cells.
Article
Oncology
Pablo Mozas, Sebastian Casanueva-Eliceiry, Andrea Rivero, Angel Serna, Marc Simo, Sonia Rodriguez, Alfredo Rivas-Delgado, Ferran Nadeu, Juan Gonzalo Correa, Juan Antonio Pineyroa, Amanda Isabel Perez-Valencia, Katia Guinetti-Ortiz, Marta Gomez-Hernando, Eva Gine, Julio Delgado, Neus Villamor, Elias Campo, Laura Magnano, Pau Abrisqueta, Xavier Setoain, Armando Lopez-Guillermo
Summary: This study explored whether total metabolic tumor volume (TMTV) and other positron emission tomography parameters can predict the time to first treatment (TTFT) for patients with follicular lymphoma (FL). The findings showed that a high TMTV is associated with other tumor burden features and can predict the duration of the observation period. This suggests that TMTV could be an important factor to consider in delaying or initiating treatment.
HEMATOLOGICAL ONCOLOGY
(2023)
Article
Oncology
C. Mircea S. Tesileanu, Sotirios Michaleas, Rocio Gonzalo Ruiz, Segundo Mariz, Babs O. Fabriek, Paula B. van Hennik, Jutta Dedorath, Bruna Dekic, Christoph Unkrig, Andreas Brandt, Janet Koenig, Harald Enzmann, Julio Delgado, Francesco Pignatti
Summary: Asciminib is an effective treatment option for patients with Philadelphia chromosome-positive chronic myeloid leukemia who have previously been treated with at least 2 TKIs. The clinical study demonstrated that asciminib had a higher MMR rate compared to the control group, indicating its efficacy and safety.
Meeting Abstract
Biotechnology & Applied Microbiology
Mireia Bachiller, Nina Barcelo, Celia Dobano-Lopez, Alba Rodriguez-Garcia, Joan Castellsague, Marta Gimenez-Alejandre, Leticia Alserawan, Julio Delgado, Marta Espanol-Rego, Mariona Pascal, Manel Juan, Patricia Perez-Galan, Alvaro Urbano-Ispizua, Sonia Guedan